Dave Stuart Speaks at ACI’s 36th Annual International Conference on the FCPA
December 16, 2019
Cravath partner David M. Stuart participated in the 36th annual “International Conference on the Foreign Corrupt Practices Act,” which was hosted by the American Conference Institute in Washington, D.C., from December 4-5, 2019. Cravath was a co‑sponsor of the event.
Dave spoke on a panel entitled “The Expected and Unexpected Impact of U.S. v. Connolly: New Considerations for Handling Internal Investigations, Individual Prosecutions, De‑Confliction and Other Government Requests.” In addition to Connolly’s implications for future investigations and enforcement, the panel discussed pressing and high‑stakes issues confronting industry and outside counsel.
Related Practices & Industries
Speakers
- Photo
-
-
M.Div., 2025, Yale Divinity School
-
J.D., 1995, New York University School of Law
-
B.A., 1990, Wesleyan UniversityPhi Beta Kappa, High Honors
Education
Related News & Insights
Deals & Cases
December 12, 2018
Cholula’s Acquisition by L Catterton
On December 12, 2018, L Catterton, a global consumer‑focused private equity firm, announced that it has entered into a definitive agreement to acquire Cholula, a leading producer and distributor of hot sauce. Cravath is representing Cholula in connection with the transaction.
Deals & Cases
SEC Closes Investigation of Insys Therapeutics Without Enforcement Action
On October 4, 2018, the SEC closed its investigation of Cravath client Insys Therapeutics without any enforcement action against the company. The investigation related to Insys’ financial restatement and disclosures, sales and marketing practices and compliance program.
Deals & Cases
Telia’s Sale of Ucell
Cravath partner David M. Stuart, assisted by associate Brooke E. Tay, advised Telia Company on U.S. compliance issues related to its sale of Uzbekistan subsidiary Ucell (FE Coscom LLC), which was announced on December 5, 2018. Cravath advised Telia on its obligations with respect to the transaction under its Deferred Prosecution Agreement with the U.S. Department of Justice (“DOJ”) , which arose out of its 2017 resolution of the DOJ’s corruption investigation. Previously, Dave and partner Rachel G. Skaistis served as lead U.S. counsel to Telia Company and its subsidiaries in the three and a half year multinational investigation, which resulted in a global resolution with the DOJ, the U.S. Securities and Exchange Commission and the Dutch Public Prosecution Service.
Deals & Cases
October 18, 2018
Novartis’s $2.1 Billion Acquisition of Endocyte
On October 18, 2018, Novartis announced that it has entered into an agreement and plan of merger with Endocyte, a US‑based biopharmaceutical company focused on developing targeted therapeutics for cancer treatment. Under the terms of the agreement, Novartis would acquire all outstanding shares of Endocyte common stock for $24 per share. This offer values Endocyte's equity at $2.1 billion. Cravath is representing Novartis in connection with the transaction.
